News 2025-01-03
Porton Achieves Higher Scores in the 2024 S & P Global ESG Assessment
Porton Pharma Solutions Ltd. is pleased to announce its achievement of a score of 44 out of 100 in the 2024 S&P Global Corporate Sustainability Assessment. This marks an improvement of 6 points compared to the previous assessment, with advancements observed across all three dimensions. (CSA Score as of November 27, 2024).
In the latest assessment, Porton’s scores increased by 3 points in the Environmental dimension, 5 points in the Social dimension, and 9 points in the Governance & Economic dimension. Significant progress was noted in areas such as Transparency and Reporting, Materiality, Climate Strategy, Labor Practices, Human Rights, and Supply Chain Management.
Guided by the ESG principles of "Green Development, Promoting Common Progress, Building a Healthy Society, and Enhancing Corporate Governance," Porton is dedicated to embedding ESG values into its corporate strategy and operations. In 2024, Porton further strengthened its ESG management by implementing various initiatives, including developing management systems, setting targets, and enhancing the quality of disclosures. Moving forward, Porton remains committed to practicing ESG principles and fostering sustainable development.
Others
More
News 2026-09-17
Porton Congratulates Partner Acepodia on FDA and NMPA IND Approvals for ACE723, a Dual-Payload ADC
This project demonstrates Porton's process-development and scale-up capabilities for complex conjugates and adds to its experience supporting innovative biopharma companies worldwide.

News 2026-09-15
Porton Chongqing Liangjiang Drug Product Manufacturing Site Earns Recertification of ISO 14001 & ISO 45001
This successful recertification highlights the standardized operation of the site's management systems, the rigor of its on-site management, and the robustness of its risk control mechanisms, further validating the continued effectiveness of the dual systems.